Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of AK117 in acute myeloid leukemia
CTR20211305Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ligufalimab in acute myeloid leukemia (AML), sponsored by Akeso, Inc.. Started Aug 2021; status: completed.
02
Drugs
ligufalimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20211305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211305.